Top

Published in:

01-02-2018 | Pancreatic Tumors

T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival

Authors: Eran Nizri, MD, PhD, Neta Sternbach, MD, Shoshi Bar-David, MSc, Amir Ben-Yehuda, MD, Fabian Gerstenhaber, MD, Tali Ofir, MD, Ido Wolf, MD, Gilad Weiner, MD, PhD, Guy Lahat, MD, Joseph Klausner, MD

Published in: Annals of Surgical Oncology | Issue 2/2018

Abstract

Background

Although lymph node (LN) metastases is considered a grave prognostic sign in pancreatic ductal adenocarcinoma (PDAC), patients with positive lymph nodes (PLN) constitute a heterogeneous group. Our purpose was to identify morphological and immune parameters in the primary tumor and in PLN of resected PDAC patients, which could further stratify these patients to different subgroups.

Methods

We retrospectively evaluated histological and immunohistochemical characteristics of 66 patients with PDAC who were operated at our institution. These were subsequently correlated to clinical outcome.

Results

Mean patient age and number of LN harvested was 65.5 ± 10.3 and 12.3 ± 6.5 years, respectively. Tumor size (T stage) and perineural invasion had no effect on clinical outcome. High-grade tumor was associated with decreased survival [overall survival (OS) = 19.6 ± 2.7 months for poorly differentiated PDAC vs. 31.2 ± 4 for well and moderately differentiated, p = 0.03]. Patients with ≥ 8 PLN had significantly worse outcome (OS = 7.3 ± 0.8 months for PLN ≥ 8 vs. OS = 30.1 ± 3.2 months for PLN < 8, p < 0.0001). T helper (Th) 1 immune response was measured both by its effector cells (CD8⁺) and expression of its main transcription factor, T-bet. CD8⁺ high patients had significantly increased OS compared with CD8⁺ low (OS = 36.8 ± 5.3 months for CD8 + high vs. OS = 24.3 ± 3.5 for CD8 + low, p = 0.03) Similarly, Th1 predominant immune response measured by T-bet expression was associated with improved OS compared with non-Th1 (OS = 32.8 ± 3.2 vs. OS = 19.5 ± 2.9, p < 0.0001).

Conclusions

Our data indicate an association between Th1-type immune response and increased survival. Future research is needed to exploit Th1 immune response as a biological marker for immunotherapy.

American Cancer Society. Cancer Facts & Figures. Atlanta: American Cancer Society; 2010.

Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10(6):323–33.CrossRefPubMed

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefPubMed

Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73(4):212–18.CrossRefPubMed

Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg. 2014;18(4):674–81.CrossRefPubMed

Perysinakis I, Avlonitis S, Georgiadou D, Tsipras H, Margaris I. Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer. ANZ J Surg. 2015;85(3):183–86.CrossRefPubMed

Lahat G, Lubezky N, Gerstenhaber F, et al. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome? World J Surg Oncol. 2016;14(1):254.CrossRefPubMedPubMedCentral

Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015;261(5):961–69.CrossRefPubMed

Basturk O, Saka B, Balci S, et al. Substaging of lymph node status in resected pancreatic ductal adenocarcinoma has strong prognostic correlations: proposal for a revised n classification for TNM staging. Ann Surg Oncol. 2015;22 Suppl 3:S1187–95.CrossRefPubMed

10.

Williams JL, Nguyen AH, Rochefort M, et al. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. J Surg Oncol. 2015;112(4):396–402.CrossRefPubMed

11.

Buc E, Couvelard A, Kwiatkowski F, et al. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion? Eur J Surg Oncol. 2014;40(11):1578–85.CrossRefPubMed

12.

Luchini C, Veronese N, Pea A, et al. Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance. Eur J Gastroenterol Hepatol. 2016;28(2):205–09.PubMed

13.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefPubMed

14.

Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S272–83.CrossRefPubMedPubMedCentral

15.

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–64.CrossRefPubMed

16.

Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–49.CrossRefPubMedPubMedCentral

17.

Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86(3):231–45.CrossRefPubMed

18.

Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.CrossRefPubMed

19.

Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654–66.CrossRefPubMed

20.

Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71(4):1263–71.CrossRefPubMed

21.

Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55.CrossRefPubMed

22.

Xu Y, Lan S, Zheng Q. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. Tumori. 2017. https://doi.org/10.5301/tj.5000624.

23.

Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–23.CrossRefPubMedPubMedCentral

24.

Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13(11):777–89.CrossRefPubMed

25.

Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997;89(4):587–96.CrossRefPubMed

26.

Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6(9):659–70.CrossRefPubMed

27.

Nizri E, Greenman-Maaravi N, Bar-David S, et al. Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival. Medicine. 2016;95(45):e5340.CrossRefPubMedPubMedCentral

28.

Bob R, Falini B, Marafioti T, Paterson JC, Pileri S, Stein H. Nodal reactive and neoplastic proliferation of monocytoid and marginal zone B cells: an immunoarchitectural and molecular study highlighting the relevance of IRTA1 and T-bet as positive markers. Histopathology. 2013;63:482–98.PubMed

29.

Feng Q, Wei H, J. M, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. 2012;127:412-9.CrossRefPubMedPubMedCentral

30.

Fu G, Miao L, Wang M, et al. The postoperative immunosuppressive phenotypes of peripheral T-helper cells are associated with poor prognosis of breast cancer patients. Immunol Investig. 2017;47(7):647-62.CrossRef

31.

Gwela A, Siddhanathi P, Chapman RW, et al. Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease. J Crohn’s Colitis. 2017;11(9):1124-34.CrossRef

32.

Delpero JR, Boher JM, Sauvanet A, et al. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the association francaise de chirurgie. Ann Surg Oncol. 2015; 22(6):1874-83.CrossRefPubMed

33.

Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191(2):154-61.CrossRefPubMed

34.

Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8.CrossRefPubMed

35.

Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10(5):437-59.CrossRefPubMed

36.

Schorn S, Demir IE, Haller B, et al. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Surg Oncol. 2017;26(1):105-15.CrossRefPubMed

37.

Johnson BA, 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for increasing pancreatic tumor immunogenicity. Clin Cancer Res. 2017;23(7):1656-69.CrossRefPubMed

Title: T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival
Authors: Eran Nizri, MD, PhD
Neta Sternbach, MD
Shoshi Bar-David, MSc
Amir Ben-Yehuda, MD
Fabian Gerstenhaber, MD
Tali Ofir, MD
Ido Wolf, MD
Gilad Weiner, MD, PhD
Guy Lahat, MD
Joseph Klausner, MD
Publication date: 01-02-2018
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 2/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-017-6237-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology

How Low Can We Go—and Should We? Risk Reduction for Minimal-Volume DCIS

Morbidity and Outcomes Following Axillary Lymphadenectomy for Melanoma: Weighing the Risk of Surgery in the Era of MSLT-II

Precision Medicine Core: Progress in Prognostication—Populations to Patients

Amputation for Sarcoma: Revisiting a 19th Century Treatment in the 21st Century

Perioperative Complications and Mortality in Patients with Urothelial Carcinoma and End-Stage Renal Disease Undergoing One-Stage Complete Urinary Tract Extirpation